Research Synthesis: NAD+ Metabolism Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the '0 cross-study disagreements' abstract claim with the biomarker-vs-function divergence explicitly surfaced in the limitations; either restate the disagreement count or rewrite the tension description to be consistent.
2. Recode directness and directional signals to align with the actual bundle content: RCTs in humans (Martens 2018, Conze 2019, Elhassan 2019, Katayoshi 2023, Christen 2026, Connell 2021, Membrez 2024 human arm, Holmes 2026) should be coded as direct or at least mixed-direct, and positive NAD+-elevation signals should be coded as positive at the source level where the bundle excerpt supports it.
3. Rewrite the Tensions and Gaps section to map the specific, named disagreements visible in the bundle (biomarker-positive vs. function-null; single-source frailty/cognition/ARDS; lack of head-to-head precursor comparisons beyond 14 days; the trigonelline pathway as an under-integrated thread) rather than generic procedural recommendations.
4. Add Membrez 2024 (trigonelline) and Holmes 2026 (NRPT/menopause) to the Findings Map narrative and ensure all 12 admitted sources are explicitly attributed to at least one mapped finding or explicit gap.
5. Add a Cognition/Critical-illness outcome row or note in the Findings Map to reflect Yulug 2023 and Gao 2026 rather than discussing them only in limitations.

Major issues

• The Findings Map's directional coding is internally inconsistent and obscures rather than maps heterogeneity: 8/12 sources are coded null/unclear yet several bundle entries (Martens 2018 NR elevates NAD+; Conze 2019 dose-dependent NAD+ increases of 22%/51%/142%; Elhassan 2019 elevated muscle NAD+ metabolome; Katayoshi 2023 elevated NAD+ metabolism; Christen 2026 NR and NMN comparably increase circulatory NAD+; Membrez 2024 shows NAD+ precursor activity) report clear positive pharmacodynamic signals, and the limitation section itself identifies a 'biomarker-versus-function divergence' across sources. The map does not faithfully represent this tension.
• The abstract states '0 cross-study disagreements across the evidence base' which directly contradicts the limitation section that surfaces a clear biomarker-positive vs. function-null divergence (Martens/Conze/Elhassan NAD+ elevation vs. Connell 2021 null functional outcomes and Chen 2024 borderline-null pooled estimate). These two claims cannot both stand.
• The Tensions and Gaps section is largely generic procedural advice ('Run adequately powered human studies… Standardize exposure, comparator…') rather than a substantive mapping of the specific disagreements visible in the bundle (e.g., the biomarker-vs-function divergence, single-source frailty/cognition/ARDS outcomes, head-to-head precursor comparison gap, the Membrez 2024 trigonelline finding as a distinct precursor pathway not integrated into the cardiometabolic or muscle map).
• The Tensions and Gaps sentence 'current direct evidence is 0/12 admitted source(s)' misclassifies the bundle: Martens 2018, Conze 2019, Elhassan 2019, Katayoshi 2023, Christen 2026, Membrez 2024, and Connell 2021 are RCTs in humans and should be coded as direct clinical evidence, not zero direct sources. The map's directness coding contradicts both the bundle content and the limitation section's own discussion of these trials.

Minor issues

• The Membrez 2024 trigonelline source is a high-relevance primary human/multi-species NAD+ precursor study that is not surfaced in the Findings Map's outcome-class narrative despite fitting Muscle Function or Frailty; it appears only in the limitations narrative.
• Outcome-class descriptions are skeletal (e.g., 'Directional coding: null=5' with no further per-source attribution) and do not attribute specific findings to specific sources within the class.
• The single-source outcomes called out in the limitations (Yulug 2023 for cognition, Gao 2026 for ARDS) are not reflected in the Findings Map table, which lists only 5 outcome classes; the cognitive and critical-illness domains are missing as explicit rows.
• The search summary's exclusion reasons state 'No records were excluded at the gates' but the admission funnel shows substantial filtering (175 → 12), creating a documentary gap in how those filtered records were handled.
• Holmes 2026 (menopause symptoms, NRPT) is not mentioned in any narrative section despite being an admitted source with a distinct clinical context.

Reviewer note

This is a thin-corpus evidence map on NAD+ metabolism with a defensible scope and generally well-attributed bundle of 12 sources. The search summary and admission funnel make the corpus boundaries auditable, and the limitations section does substantive work in identifying the biomarker-vs-function divergence, single-source outcomes, and the lack of hard-endpoint trials. However, several internal inconsistencies prevent acceptance: the abstract's '0 cross-study disagreements' claim directly contradicts the limitation section's own surfacing of the Martens/Conze/Elhassan vs. Connell/Chen divergence; the directness coding misclassifies human RCTs as non-direct; the Tensions and Gaps section is generic rather than mapping the named disagreements visible in the bundle; and at least two admitted sources (Membrez 2024, Holmes 2026) are not surfaced in the Findings Map narrative. These are bounded fixes — the underlying sources and evidence are real and the limitations narrative already does much of the analytic work — so the appropriate call is revise, not reject. Fixing the coding inconsistencies, rewriting Tensions and Gaps to name the specific divergences, and ensuring all 12 sources are explicitly attributed will bring this to accept quality.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis